Paysign

Paysign generates revenue through fees on prepaid card programs — card issuance, transaction processing, maintenance fees, and interchange income — primarily serving two verticals: patient affordability programs (co-pay assistance, clinical trial payments) and plasma donor compensation. The company manufactures and distributes physical and virtual prepaid cards that pharmaceutical companies fund for patient use at pharmacies, while plasma centers load donation compensation directly onto donor cards, per the firm's annual SEC filings.

Paysign is an operating company, not an investment firm — CEO Mark Newcomer, CFO Jeff Baker, and the board of directors make capital-allocation decisions. The company's treasury strategy concentrates on operational reinvestment, technology development, and occasional tuck-in acquisitions rather than external portfolio management. There is no investment committee allocating to third-party funds or direct deals.

Client acquisition follows a B2B enterprise sales model: the company targets pharmaceutical manufacturers with patient assistance obligations, large plasma collection networks seeking standardized donor compensation, and corporations managing employee rewards and per-diem programs. Contracts are typically multi-year, embedded in facility-level point-of-sale integrations — a plasma network adopting Paysign commits hundreds of collection centers to a single payment platform, creating high switching costs.

Paysign does not make co-investments or commit capital to external funds. It is a publicly traded operating company (Nasdaq: PAYS) that deploys its balance sheet toward platform development, compliance infrastructure, and operational scaling — not LP-style investing. Institutional allocators encountering Paysign are evaluating it as a public equity or potential strategic acquirer, not a fund commitment counterparty.

The company does not operate in consumer-direct general spending cards, cryptocurrency platforms, or international remittance. While Paysign holds prepaid card intellectual property, its revenue concentration in pharma co-pay and plasma verticals means it intentionally avoids retail gift cards, payroll cards, and traditional BaaS challenger-banking use cases, per the firm's earnings commentary and investor materials.

Paysign contracts directly with plasma collection center operators — including large national networks such as those under ownership of global pharmaceutical companies — to provide branded reloadable cards as the exclusive donor payment method. Donors receive compensation for each plasma donation loaded onto a Paysign card, which functions on the Discover or Mastercard network. The company earns card program fees, monthly maintenance fees per active account, and interchange on cardholder spending.

No charitable foundation, donor-advised fund, or philanthropic vehicle is associated with Paysign. As a Nasdaq-listed operating company, any corporate giving flows through standard corporate social responsibility budgeting, not through a separate family-office-style foundation — consistent with a publicly traded enterprise not backed by a single-family wealth origin.